- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05058651
Avaliação da adição do medicamento imunoterápico atezolizumabe ao tratamento quimioterápico padrão para carcinomas neuroendócrinos avançados ou metastáticos com origem fora do pulmão
Randomized Phase II/III Trial of First Line Platinum/Etoposide With or Without Atezolizumab (NSC#783608) in Patients With Advanced or Metastatic Poorly Differentiated Extrapulmonary Neuroendocrine Carcinomas (NEC)
This phase II/III trial compares the effect of immunotherapy with atezolizumab in combination with standard chemotherapy with a platinum drug (cisplatin or carboplatin) and etoposide versus standard therapy alone for the treatment of poorly differentiated extrapulmonary (originated outside the lung) neuroendocrine cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic). The other aim of this trial is to compare using atezolizumab just at the beginning of treatment versus continuing it beyond the initial treatment. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Cisplatin and carboplatin are in a class of medications known as platinum-containing compounds that work by killing, stopping or slowing the growth of cancer cells. Etoposide is in a class of medications known as podophyllotoxin derivatives. It blocks a certain enzyme needed for cell division and DNA repair, and it may kill cancer cells. Giving atezolizumab in combination with a platinum drug (cisplatin or carboplatin) and etoposide may work better in treating patients with poorly differentiated extrapulmonary neuroendocrine cancer compared to standard therapy with a platinum drug (cisplatin or carboplatin) and etoposide alone.
Visão geral do estudo
Status
Condições
Descrição detalhada
PRIMARY OBJECTIVES:
I. Compare the combination of induction platinum/etoposide and atezolizumab followed by maintenance atezolizumab (Arm 1) versus induction platinum/etoposide alone (Arm 3).
II. Compare the combination of induction platinum/etoposide and atezolizumab followed by observation (Arm 2) versus induction platinum/etoposide alone (Arm 3).
III. Compare the combination of induction platinum/etoposide and atezolizumab followed by maintenance atezolizumab (Arm 1) versus the combination of induction platinum/etoposide and atezolizumab followed by observation (Arm 2).
SECONDARY OBJECTIVES:
I. To compare overall survival (OS), measured from start of observation/maintenance, across arms.
II. To compare progression free survival (PFS) (measured from randomization and measured from start of observation/maintenance) across arms.
III. To compare objective response rate (ORR = confirmed and unconfirmed partial response [PR] + confirmed and unconfirmed complete response [CR]) across arms among patients with measurable disease at randomization.
IV. To compare clinical benefit rate (CBR = confirmed and unconfirmed PR + confirmed and unconfirmed CR + stable disease [SD]) across arms among patients with measurable disease at randomization.
V. To compare duration of response (DOR) across arms. VI. To evaluate the safety and tolerability of each arm.
ADDITIONAL OBJECTIVE:
I. To bank tumor and blood samples for future biomarker correlative studies.
OUTLINE: Patients are randomized to 1 of 3 arms.
ARM I: During induction phase, patients receive atezolizumab intravenously (IV) over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity.
ARM II (CLOSED TO ACCRUAL 7/9/26): During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year.
ARM III: During induction phase, patients receive carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year.
Patients in all arms also undergo computed tomography (CT) scan and/or magnetic resonance imaging (MRI) throughout the trial and blood sample collection on study.
After completion of study treatment, patients are followed up for 5 years.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 3
Contactos e Locais
Locais de estudo
-
-
Alaska
-
Anchorage, Alaska, Estados Unidos, 99508
- Suspenso
- Alaska Women's Cancer Care
-
-
Arizona
-
Phoenix, Arizona, Estados Unidos, 85004
- Recrutamento
- Cancer Center at Saint Joseph's
-
Investigador principal:
- Loretta J. Nastoupil
-
Contato:
- Site Public Contact
- Número de telefone: 720-874-1881
- E-mail: ResearchInstituteInquiries@CommonSpirit.org
-
Phoenix, Arizona, Estados Unidos, 85054
- Recrutamento
- Mayo Clinic Hospital in Arizona
-
Investigador principal:
- Jacob Orme
-
Contato:
- Site Public Contact
- Número de telefone: 855-776-0015
-
-
California
-
Anaheim, California, Estados Unidos, 92806
- Recrutamento
- Kaiser Permanente-Anaheim
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Helen H. Moon
-
Auburn, California, Estados Unidos, 95602
- Recrutamento
- Sutter Auburn Faith Hospital
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Auburn, California, Estados Unidos, 95603
- Recrutamento
- Sutter Cancer Centers Radiation Oncology Services-Auburn
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Baldwin Park, California, Estados Unidos, 91706
- Recrutamento
- Kaiser Permanente-Baldwin Park
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Helen H. Moon
-
Bellflower, California, Estados Unidos, 90706
- Recrutamento
- Kaiser Permanente-Bellflower
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Helen H. Moon
-
Berkeley, California, Estados Unidos, 94704
- Recrutamento
- Alta Bates Summit Medical Center-Herrick Campus
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Cameron Park, California, Estados Unidos, 95682
- Recrutamento
- Sutter Cancer Centers Radiation Oncology Services-Cameron Park
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Carmichael, California, Estados Unidos, 95608
- Recrutamento
- Mercy San Juan Medical Center
-
Investigador principal:
- Loretta J. Nastoupil
-
Contato:
- Site Public Contact
- Número de telefone: 720-874-1881
- E-mail: ResearchInstituteInquiries@commonspirit.org
-
Carmichael, California, Estados Unidos, 95608
- Recrutamento
- Mercy Cancer Center - Carmichael
-
Investigador principal:
- Loretta J. Nastoupil
-
Contato:
- Site Public Contact
- Número de telefone: 720-874-1881
- E-mail: ResearchInstituteInquiries@CommonSpirit.org
-
Elk Grove, California, Estados Unidos, 95758
- Recrutamento
- Mercy Cancer Center - Elk Grove
-
Investigador principal:
- Loretta J. Nastoupil
-
Contato:
- Site Public Contact
- Número de telefone: 720-874-1881
- E-mail: ResearchInstituteInquiries@CommonSpirit.org
-
Fontana, California, Estados Unidos, 92335
- Recrutamento
- Kaiser Permanente-Fontana
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Helen H. Moon
-
Fremont, California, Estados Unidos, 94538
- Recrutamento
- Palo Alto Medical Foundation-Fremont
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Harbor City, California, Estados Unidos, 90710
- Recrutamento
- Kaiser Permanente South Bay
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Helen H. Moon
-
Irvine, California, Estados Unidos, 92618
- Recrutamento
- Kaiser Permanente-Irvine
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Helen H. Moon
-
Los Angeles, California, Estados Unidos, 90027
- Recrutamento
- Kaiser Permanente Los Angeles Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Helen H. Moon
-
Los Angeles, California, Estados Unidos, 90034
- Recrutamento
- Kaiser Permanente West Los Angeles
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Helen H. Moon
-
Modesto, California, Estados Unidos, 95355
- Recrutamento
- Memorial Medical Center
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Mountain View, California, Estados Unidos, 94040
- Recrutamento
- Palo Alto Medical Foundation-Camino Division
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Ontario, California, Estados Unidos, 91761
- Recrutamento
- Kaiser Permanente-Ontario
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Helen H. Moon
-
Palo Alto, California, Estados Unidos, 94301
- Recrutamento
- Palo Alto Medical Foundation Health Care
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Panorama City, California, Estados Unidos, 91402
- Recrutamento
- Kaiser Permanente - Panorama City
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Helen H. Moon
-
Riverside, California, Estados Unidos, 92505
- Recrutamento
- Kaiser Permanente-Riverside
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Helen H. Moon
-
Rocklin, California, Estados Unidos, 95765
- Recrutamento
- Mercy Cancer Center - Rocklin
-
Investigador principal:
- Loretta J. Nastoupil
-
Contato:
- Site Public Contact
- Número de telefone: 720-874-1881
- E-mail: ResearchInstituteInquiries@CommonSpirit.org
-
Roseville, California, Estados Unidos, 95661
- Recrutamento
- Sutter Cancer Centers Radiation Oncology Services-Roseville
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Roseville, California, Estados Unidos, 95661
- Recrutamento
- Sutter Roseville Medical Center
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Sacramento, California, Estados Unidos, 95816
- Recrutamento
- Sutter Medical Center Sacramento
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Sacramento, California, Estados Unidos, 95816
- Recrutamento
- Mercy Cancer Center - Sacramento
-
Investigador principal:
- Loretta J. Nastoupil
-
Contato:
- Site Public Contact
- Número de telefone: 720-874-1881
- E-mail: ResearchInstituteInquiries@CommonSpirit.org
-
San Diego, California, Estados Unidos, 92120
- Recrutamento
- Kaiser Permanente-San Diego Zion
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Helen H. Moon
-
San Francisco, California, Estados Unidos, 94115
- Recrutamento
- California Pacific Medical Center-Pacific Campus
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
San Marcos, California, Estados Unidos, 92078
- Recrutamento
- Kaiser Permanente-San Marcos
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Helen H. Moon
-
Santa Cruz, California, Estados Unidos, 95065
- Recrutamento
- Palo Alto Medical Foundation-Santa Cruz
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Santa Rosa, California, Estados Unidos, 95403
- Recrutamento
- Sutter Pacific Medical Foundation
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- Número de telefone: 415-209-2683
- E-mail: clinicalresearch@sutterhealth.org
-
Sunnyvale, California, Estados Unidos, 94086
- Recrutamento
- Palo Alto Medical Foundation-Sunnyvale
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Vallejo, California, Estados Unidos, 94589
- Recrutamento
- Sutter Solano Medical Center/Cancer Center
-
Investigador principal:
- Kristie A. Bobolis
-
Contato:
- Site Public Contact
- E-mail: clinicalresearch@sutterhealth.org
-
Woodland, California, Estados Unidos, 95695
- Recrutamento
- Woodland Memorial Hospital
-
Investigador principal:
- Loretta J. Nastoupil
-
Contato:
- Site Public Contact
- Número de telefone: 720-874-1881
- E-mail: ResearchInstituteInquiries@CommonSpirit.org
-
Woodland Hills, California, Estados Unidos, 91367
- Recrutamento
- Kaiser Permanente-Woodland Hills
-
Contato:
- Site Public Contact
- Número de telefone: 800-398-3996
- E-mail: clinical.trials@kp.org
-
Investigador principal:
- Helen H. Moon
-
-
Colorado
-
Denver, Colorado, Estados Unidos, 80210
- Recrutamento
- AdventHealth Porter
-
Contato:
- Site Public Contact
- E-mail: research.institute@adventhealth.com
-
Investigador principal:
- Yousuf A. Gaffar
-
Littleton, Colorado, Estados Unidos, 80122
- Recrutamento
- AdventHealth Littleton
-
Contato:
- Site Public Contact
- E-mail: research.institute@adventhealth.com
-
Investigador principal:
- Yousuf A. Gaffar
-
Parker, Colorado, Estados Unidos, 80138
- Recrutamento
- AdventHealth Parker
-
Contato:
- Site Public Contact
- E-mail: research.institute@adventhealth.com
-
Investigador principal:
- Yousuf A. Gaffar
-
-
Connecticut
-
Derby, Connecticut, Estados Unidos, 06418
- Recrutamento
- Smilow Cancer Hospital-Derby Care Center
-
Contato:
- Site Public Contact
- Número de telefone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Investigador principal:
- Matthew Austin
-
Fairfield, Connecticut, Estados Unidos, 06824
- Recrutamento
- Smilow Cancer Hospital Care Center-Fairfield
-
Contato:
- Site Public Contact
- Número de telefone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Investigador principal:
- Matthew Austin
-
Glastonbury, Connecticut, Estados Unidos, 06033
- Suspenso
- Smilow Cancer Hospital Care Center at Glastonbury
-
Greenwich, Connecticut, Estados Unidos, 06830
- Recrutamento
- Smilow Cancer Hospital Care Center at Greenwich
-
Contato:
- Site Public Contact
- Número de telefone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Investigador principal:
- Matthew Austin
-
Guilford, Connecticut, Estados Unidos, 06437
- Recrutamento
- Smilow Cancer Hospital Care Center - Guilford
-
Contato:
- Site Public Contact
- Número de telefone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Investigador principal:
- Matthew Austin
-
Hartford, Connecticut, Estados Unidos, 06105
- Suspenso
- Smilow Cancer Hospital Care Center at Saint Francis
-
New Haven, Connecticut, Estados Unidos, 06520
- Recrutamento
- Yale University
-
Contato:
- Site Public Contact
- Número de telefone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Investigador principal:
- Matthew Austin
-
North Haven, Connecticut, Estados Unidos, 06473
- Recrutamento
- Yale-New Haven Hospital North Haven Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Investigador principal:
- Matthew Austin
-
Stamford, Connecticut, Estados Unidos, 06902
- Recrutamento
- Smilow Cancer Hospital Care Center at Long Ridge
-
Contato:
- Site Public Contact
- Número de telefone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Investigador principal:
- Matthew Austin
-
Torrington, Connecticut, Estados Unidos, 06790
- Recrutamento
- Smilow Cancer Hospital-Torrington Care Center
-
Contato:
- Site Public Contact
- Número de telefone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Investigador principal:
- Matthew Austin
-
Trumbull, Connecticut, Estados Unidos, 06611
- Recrutamento
- Smilow Cancer Hospital Care Center-Trumbull
-
Contato:
- Site Public Contact
- Número de telefone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Investigador principal:
- Matthew Austin
-
Waterbury, Connecticut, Estados Unidos, 06708
- Recrutamento
- Smilow Cancer Hospital-Waterbury Care Center
-
Contato:
- Site Public Contact
- Número de telefone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Investigador principal:
- Matthew Austin
-
Waterford, Connecticut, Estados Unidos, 06385
- Recrutamento
- Smilow Cancer Hospital Care Center - Waterford
-
Contato:
- Site Public Contact
- Número de telefone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Investigador principal:
- Matthew Austin
-
-
Florida
-
Fort Lauderdale, Florida, Estados Unidos, 33308
- Recrutamento
- Holy Cross Hospital
-
Investigador principal:
- Tareq Al baghdadi
-
Contato:
- Site Public Contact
- E-mail: eileen.georgi@holy-cross.com
-
Jacksonville, Florida, Estados Unidos, 32224-9980
- Recrutamento
- Mayo Clinic in Florida
-
Investigador principal:
- Jacob Orme
-
Contato:
- Site Public Contact
- Número de telefone: 855-776-0015
-
Tampa, Florida, Estados Unidos, 33612
- Recrutamento
- Moffitt Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-679-0775
- E-mail: ClinicalTrials@moffitt.org
-
Investigador principal:
- Mintallah Haider
-
-
Hawaii
-
Honolulu, Hawaii, Estados Unidos, 96813
- Recrutamento
- Hawaii Cancer Care Inc - Waterfront Plaza
-
Contato:
- Site Public Contact
- Número de telefone: 808-524-6115
- E-mail: i.webster@hawaiicancercare.com
-
Investigador principal:
- Elizabeth S. Nakasone
-
Honolulu, Hawaii, Estados Unidos, 96813
- Recrutamento
- Queen's Cancer Cenrer - POB I
-
Contato:
- Site Public Contact
- Número de telefone: 808-532-0315
-
Investigador principal:
- Elizabeth S. Nakasone
-
Honolulu, Hawaii, Estados Unidos, 96813
- Recrutamento
- Queen's Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 808-545-8548
-
Investigador principal:
- Elizabeth S. Nakasone
-
Honolulu, Hawaii, Estados Unidos, 96813
- Recrutamento
- Straub Clinic and Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 808-522-4333
-
Investigador principal:
- Elizabeth S. Nakasone
-
Honolulu, Hawaii, Estados Unidos, 96813
- Recrutamento
- University of Hawaii Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 808-586-2979
-
Investigador principal:
- Elizabeth S. Nakasone
-
Honolulu, Hawaii, Estados Unidos, 96817
- Recrutamento
- Queen's Cancer Center - Kuakini
-
Contato:
- Site Public Contact
- Número de telefone: 808-531-8521
-
Investigador principal:
- Elizabeth S. Nakasone
-
‘Aiea, Hawaii, Estados Unidos, 96701
- Recrutamento
- Hawaii Cancer Care - Westridge
-
Contato:
- Site Public Contact
- Número de telefone: 808-539-2273
- E-mail: info@hawaiicancercare.com
-
Investigador principal:
- Elizabeth S. Nakasone
-
‘Aiea, Hawaii, Estados Unidos, 96701
- Suspenso
- Pali Momi Medical Center
-
‘Ewa Beach, Hawaii, Estados Unidos, 96706
- Recrutamento
- The Queen's Medical Center - West Oahu
-
Contato:
- Site Public Contact
- E-mail: rohta@queens.org
-
Investigador principal:
- Elizabeth S. Nakasone
-
-
Idaho
-
Coeur d'Alene, Idaho, Estados Unidos, 83814
- Recrutamento
- Kootenai Health - Coeur d'Alene
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Nampa, Idaho, Estados Unidos, 83687
- Recrutamento
- Saint Alphonsus Cancer Care Center-Nampa
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Investigador principal:
- Tareq Al baghdadi
-
Post Falls, Idaho, Estados Unidos, 83854
- Recrutamento
- Kootenai Clinic Cancer Services - Post Falls
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Sandpoint, Idaho, Estados Unidos, 83864
- Recrutamento
- Kootenai Clinic Cancer Services - Sandpoint
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
Illinois
-
Aurora, Illinois, Estados Unidos, 60504
- Suspenso
- Rush-Copley Medical Center
-
Centralia, Illinois, Estados Unidos, 62801
- Recrutamento
- Centralia Oncology Clinic
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Chicago, Illinois, Estados Unidos, 60637
- Recrutamento
- University of Chicago Comprehensive Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Investigador principal:
- Ardaman Shergill
-
Chicago, Illinois, Estados Unidos, 60611
- Recrutamento
- Northwestern University
-
Investigador principal:
- Mary F. Mulcahy
-
Contato:
- Site Public Contact
- Número de telefone: 312-695-1301
- E-mail: cancer@northwestern.edu
-
Danville, Illinois, Estados Unidos, 61832
- Recrutamento
- Carle at The Riverfront
-
Investigador principal:
- Vamsi K. Vasireddy
-
Contato:
- Site Public Contact
- Número de telefone: 800-446-5532
- E-mail: Research@Carle.com
-
DeKalb, Illinois, Estados Unidos, 60115
- Recrutamento
- Northwestern Medicine Cancer Center Kishwaukee
-
Investigador principal:
- Mary F. Mulcahy
-
Contato:
- Site Public Contact
- Número de telefone: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Decatur, Illinois, Estados Unidos, 62526
- Recrutamento
- Cancer Care Specialists of Illinois - Decatur
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Decatur, Illinois, Estados Unidos, 62526
- Recrutamento
- Decatur Memorial Hospital
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Effingham, Illinois, Estados Unidos, 62401
- Recrutamento
- Carle Physician Group-Effingham
-
Contato:
- Site Public Contact
- Número de telefone: 800-446-5532
- E-mail: Research@carle.com
-
Investigador principal:
- Vamsi K. Vasireddy
-
Effingham, Illinois, Estados Unidos, 62401
- Recrutamento
- Crossroads Cancer Center
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Geneva, Illinois, Estados Unidos, 60134
- Recrutamento
- Northwestern Medicine Cancer Center Delnor
-
Investigador principal:
- Mary F. Mulcahy
-
Contato:
- Site Public Contact
- Número de telefone: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Glenview, Illinois, Estados Unidos, 60026
- Recrutamento
- Northwestern Medicine Glenview Outpatient Center
-
Investigador principal:
- Mary F. Mulcahy
-
Contato:
- Site Public Contact
- Número de telefone: 312-695-1102
-
Grayslake, Illinois, Estados Unidos, 60030
- Recrutamento
- Northwestern Medicine Grayslake Outpatient Center
-
Investigador principal:
- Mary F. Mulcahy
-
Contato:
- Site Public Contact
- Número de telefone: 312-695-1102
-
Harvey, Illinois, Estados Unidos, 60426
- Recrutamento
- Ingalls Memorial Hospital
-
Investigador principal:
- James A. Wallace
-
Contato:
- Site Public Contact
- Número de telefone: 708-915-4673
- E-mail: clinicaltrials@ingalls.org
-
Lake Forest, Illinois, Estados Unidos, 60045
- Recrutamento
- Northwestern Medicine Lake Forest Hospital
-
Investigador principal:
- Mary F. Mulcahy
-
Contato:
- Site Public Contact
- E-mail: cancertrials@northwestern.edu
-
Mattoon, Illinois, Estados Unidos, 61938
- Recrutamento
- Carle Physician Group-Mattoon/Charleston
-
Contato:
- Site Public Contact
- Número de telefone: 800-446-5532
- E-mail: Research@carle.com
-
Investigador principal:
- Vamsi K. Vasireddy
-
Mount Vernon, Illinois, Estados Unidos, 62864
- Recrutamento
- SSM Health Good Samaritan
-
Investigador principal:
- Jay W. Carlson
-
Contato:
- Site Public Contact
- Número de telefone: 618-899-1894
- E-mail: gayla.hall@ssmhealth.com
-
New Lenox, Illinois, Estados Unidos, 60451
- Recrutamento
- UC Comprehensive Cancer Center at Silver Cross
-
Contato:
- Site Public Contact
- Número de telefone: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Investigador principal:
- Ardaman Shergill
-
Normal, Illinois, Estados Unidos, 61761
- Recrutamento
- Carle BroMenn Medical Center
-
Investigador principal:
- Vamsi K. Vasireddy
-
Contato:
- Site Public Contact
- Número de telefone: 800-446-5532
- E-mail: Research@Carle.com
-
Normal, Illinois, Estados Unidos, 61761
- Recrutamento
- Carle Cancer Institute Normal
-
Investigador principal:
- Vamsi K. Vasireddy
-
Contato:
- Site Public Contact
- Número de telefone: 800-446-5532
- E-mail: Research@Carle.com
-
O'Fallon, Illinois, Estados Unidos, 62269
- Recrutamento
- Cancer Care Center of O'Fallon
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-876-4762
- E-mail: morganthaler.jodi@mhsil.com
-
Orland Park, Illinois, Estados Unidos, 60462
- Recrutamento
- University of Chicago Medicine-Orland Park
-
Contato:
- Site Public Contact
- Número de telefone: 773-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
Investigador principal:
- Ardaman Shergill
-
Orland Park, Illinois, Estados Unidos, 60462
- Recrutamento
- Northwestern Medicine Orland Park
-
Investigador principal:
- Mary F. Mulcahy
-
Contato:
- Site Public Contact
- E-mail: nctnprogram_rhlccc@northwestern.edu
-
Rockford, Illinois, Estados Unidos, 61114
- Recrutamento
- UW Health Carbone Cancer Center Rockford
-
Contato:
- Site Public Contact
- Número de telefone: 779-696-9378
- E-mail: lkline@uwhealth.org
-
Investigador principal:
- Fahrettin Covut
-
Springfield, Illinois, Estados Unidos, 62702
- Recrutamento
- Southern Illinois University School of Medicine
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-545-7929
-
Springfield, Illinois, Estados Unidos, 62702
- Recrutamento
- Springfield Clinic
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 800-444-7541
-
Springfield, Illinois, Estados Unidos, 62781
- Recrutamento
- Springfield Memorial Hospital
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 217-528-7541
- E-mail: pallante.beth@mhsil.com
-
Urbana, Illinois, Estados Unidos, 61801
- Recrutamento
- Carle Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-446-5532
- E-mail: Research@carle.com
-
Investigador principal:
- Vamsi K. Vasireddy
-
Warrenville, Illinois, Estados Unidos, 60555
- Recrutamento
- Northwestern Medicine Cancer Center Warrenville
-
Investigador principal:
- Mary F. Mulcahy
-
Contato:
- Site Public Contact
- Número de telefone: 630-352-5360
- E-mail: Donald.Smith3@nm.org
-
Yorkville, Illinois, Estados Unidos, 60560
- Suspenso
- Rush-Copley Healthcare Center
-
-
Indiana
-
Crown Point, Indiana, Estados Unidos, 46307
- Recrutamento
- UChicago Medicine Northwest Indiana
-
Investigador principal:
- Ardaman Shergill
-
Contato:
- Site Public Contact
- Número de telefone: 855-702-8222
- E-mail: cancerclinicaltrials@bsd.uchicago.edu
-
-
Iowa
-
Ames, Iowa, Estados Unidos, 50010
- Recrutamento
- Mary Greeley Medical Center
-
Investigador principal:
- Joseph J. Merchant
-
Contato:
- Site Public Contact
- Número de telefone: 515-956-4132
-
Ames, Iowa, Estados Unidos, 50010
- Recrutamento
- McFarland Clinic - Ames
-
Investigador principal:
- Joseph J. Merchant
-
Contato:
- Site Public Contact
- Número de telefone: 515-239-4734
- E-mail: ksoder@mcfarlandclinic.com
-
Ankeny, Iowa, Estados Unidos, 50023
- Recrutamento
- UI Health Care Mission Cancer and Blood - Ankeny Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-3305
-
Investigador principal:
- Seema Harichand-Herdt
-
Boone, Iowa, Estados Unidos, 50036
- Suspenso
- McFarland Clinic - Boone
-
Carroll, Iowa, Estados Unidos, 51401
- Recrutamento
- Saint Anthony Regional Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 515-689-7658
- E-mail: sbenson@iora.org
-
Investigador principal:
- Seema Harichand-Herdt
-
Clive, Iowa, Estados Unidos, 50325
- Recrutamento
- Mercy Cancer Center-West Lakes
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-3305
-
Investigador principal:
- Richard L. Deming
-
Clive, Iowa, Estados Unidos, 50325
- Recrutamento
- UI Health Care Mission Cancer and Blood - West Des Moines Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-3305
-
Investigador principal:
- Seema Harichand-Herdt
-
Creston, Iowa, Estados Unidos, 50801
- Ativo, não recrutando
- Greater Regional Medical Center
-
Des Moines, Iowa, Estados Unidos, 50314
- Recrutamento
- Broadlawns Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 515-282-2200
-
Investigador principal:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Estados Unidos, 50314
- Recrutamento
- Mercy Medical Center - Des Moines
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-3305
-
Investigador principal:
- Richard L. Deming
-
Des Moines, Iowa, Estados Unidos, 50309
- Recrutamento
- Iowa Methodist Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-6727
-
Investigador principal:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Estados Unidos, 50309
- Recrutamento
- UI Health Care Mission Cancer and Blood - Des Moines Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-3305
-
Investigador principal:
- Seema Harichand-Herdt
-
Des Moines, Iowa, Estados Unidos, 50314
- Recrutamento
- UI Health Care Mission Cancer and Blood - Laurel Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-3305
-
Investigador principal:
- Seema Harichand-Herdt
-
Fort Dodge, Iowa, Estados Unidos, 50501
- Recrutamento
- McFarland Clinic - Trinity Cancer Center
-
Investigador principal:
- Joseph J. Merchant
-
Contato:
- Site Public Contact
- Número de telefone: 515-956-4132
-
Jefferson, Iowa, Estados Unidos, 50129
- Suspenso
- McFarland Clinic - Jefferson
-
Marshalltown, Iowa, Estados Unidos, 50158
- Recrutamento
- McFarland Clinic - Marshalltown
-
Investigador principal:
- Joseph J. Merchant
-
Contato:
- Site Public Contact
- Número de telefone: 515-956-4132
-
Waukee, Iowa, Estados Unidos, 50263
- Recrutamento
- UI Health Care Mission Cancer and Blood - Waukee Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-3305
-
Investigador principal:
- Seema Harichand-Herdt
-
West Des Moines, Iowa, Estados Unidos, 50266
- Recrutamento
- Mercy Medical Center-West Lakes
-
Contato:
- Site Public Contact
- Número de telefone: 515-241-3305
-
Investigador principal:
- Richard L. Deming
-
-
Louisiana
-
Baton Rouge, Louisiana, Estados Unidos, 70805
- Recrutamento
- LSU Health Baton Rouge-North Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 225-765-7659
- E-mail: research@ololrmc.com
-
Investigador principal:
- Marshall P. Stagg
-
Baton Rouge, Louisiana, Estados Unidos, 70808
- Recrutamento
- Our Lady of the Lake Physician Group
-
Contato:
- Site Public Contact
- Número de telefone: 225-765-7659
- E-mail: research@ololrmc.com
-
Investigador principal:
- Marshall P. Stagg
-
Metairie, Louisiana, Estados Unidos, 70006
- Recrutamento
- East Jefferson General Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 504-210-3539
- E-mail: emede1@lsuhsc.edu
-
Investigador principal:
- Tara Castellano
-
Metairie, Louisiana, Estados Unidos, 70006
- Recrutamento
- LSU Healthcare Network / Metairie Multi-Specialty Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 504-210-3539
- E-mail: emede1@lsuhsc.edu
-
Investigador principal:
- Tara Castellano
-
New Orleans, Louisiana, Estados Unidos, 70112
- Recrutamento
- University Medical Center New Orleans
-
Contato:
- Site Public Contact
- Número de telefone: 504-210-3539
- E-mail: emede1@lsuhsc.edu
-
Investigador principal:
- Tara Castellano
-
-
Massachusetts
-
Burlington, Massachusetts, Estados Unidos, 01805
- Recrutamento
- Lahey Clinic
-
Contato:
- Site Public Contact
- Número de telefone: 781-744-3421
- E-mail: lhmc-cancer-clinical-trials@lahey.org
-
Investigador principal:
- Andrew Piper-Vallillo
-
Peabody, Massachusetts, Estados Unidos, 01960
- Recrutamento
- Lahey Clinic Peabody
-
Contato:
- Site Public Contact
- Número de telefone: 781-744-3421
- E-mail: lhmc-cancer-clinical-trials@lahey.org
-
Investigador principal:
- Andrew Piper-Vallillo
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Recrutamento
- University of Michigan Rogel Cancer Center
-
Investigador principal:
- Vaibhav Sahai
-
Contato:
- Site Public Contact
- Número de telefone: 800-865-1125
- E-mail: CancerAnswerLine@med.umich.edu
-
Ann Arbor, Michigan, Estados Unidos, 48106
- Recrutamento
- Trinity Health Saint Joseph Mercy Hospital Ann Arbor
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Battle Creek, Michigan, Estados Unidos, 49017
- Recrutamento
- Bronson Battle Creek
-
Contato:
- Site Public Contact
- Número de telefone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Kathleen Y. Butler
-
Brighton, Michigan, Estados Unidos, 48114
- Recrutamento
- Trinity Health IHA Medical Group Hematology Oncology - Brighton
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Brighton, Michigan, Estados Unidos, 48114
- Recrutamento
- Trinity Health Medical Center - Brighton
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Brownstown, Michigan, Estados Unidos, 48183
- Recrutamento
- Henry Ford Cancer Institute-Downriver
-
Contato:
- Site Public Contact
- Número de telefone: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Investigador principal:
- Haythem Y. Ali
-
Canton, Michigan, Estados Unidos, 48188
- Recrutamento
- Trinity Health IHA Medical Group Hematology Oncology - Canton
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Canton, Michigan, Estados Unidos, 48188
- Recrutamento
- Trinity Health Medical Center - Canton
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Chelsea, Michigan, Estados Unidos, 48118
- Recrutamento
- Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Chelsea, Michigan, Estados Unidos, 48118
- Recrutamento
- Chelsea Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Clinton Township, Michigan, Estados Unidos, 48038
- Recrutamento
- Henry Ford Macomb Hospital-Clinton Township
-
Contato:
- Site Public Contact
- Número de telefone: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Investigador principal:
- Haythem Y. Ali
-
Dearborn, Michigan, Estados Unidos, 48126
- Recrutamento
- Henry Ford Medical Center-Fairlane
-
Contato:
- Site Public Contact
- Número de telefone: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Investigador principal:
- Haythem Y. Ali
-
Dearborn, Michigan, Estados Unidos, 48124
- Recrutamento
- Corewell Health Dearborn Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 248-551-7695
-
Investigador principal:
- Andrew A. Muskovitz
-
Detroit, Michigan, Estados Unidos, 48202
- Recrutamento
- Henry Ford Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Investigador principal:
- Haythem Y. Ali
-
Detroit, Michigan, Estados Unidos, 48201
- Ativo, não recrutando
- Wayne State University/Karmanos Cancer Institute
-
Detroit, Michigan, Estados Unidos, 48236
- Recrutamento
- Henry Ford Health Saint John Hospital
-
Investigador principal:
- Tareq Al baghdadi
-
Contato:
- Site Public Contact
- Número de telefone: 313-343-3166
- E-mail: Kkeenan1@hfhs.org
-
East China Township, Michigan, Estados Unidos, 48054
- Recrutamento
- Henry Ford River District Hospital
-
Investigador principal:
- Tareq Al baghdadi
-
Contato:
- Site Public Contact
- Número de telefone: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Farmington Hills, Michigan, Estados Unidos, 48334
- Ativo, não recrutando
- Weisberg Cancer Treatment Center
-
Farmington Hills, Michigan, Estados Unidos, 48336
- Recrutamento
- Corewell Health Farmington Hills Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 248-551-7695
-
Investigador principal:
- Andrew A. Muskovitz
-
Flint, Michigan, Estados Unidos, 48503
- Recrutamento
- Genesys Hurley Cancer Institute
-
Contato:
- Site Public Contact
- Número de telefone: 810-762-8038
- E-mail: wstrong@ghci.org
-
Investigador principal:
- Tareq Al baghdadi
-
Flint, Michigan, Estados Unidos, 48503
- Recrutamento
- Hurley Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 810-762-8038
- E-mail: wstrong@ghci.org
-
Investigador principal:
- Tareq Al baghdadi
-
Flint, Michigan, Estados Unidos, 48503
- Suspenso
- Genesee Hematology Oncology PC
-
Flint, Michigan, Estados Unidos, 48503
- Recrutamento
- Cancer Hematology Centers - Flint
-
Contato:
- Site Public Contact
- Número de telefone: 810-762-8038
- E-mail: wstrong@ghci.org
-
Investigador principal:
- Tareq Al baghdadi
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Recrutamento
- Trinity Health Grand Rapids Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Tareq Al baghdadi
-
Grand Rapids, Michigan, Estados Unidos, 49503
- Recrutamento
- Corewell Health Grand Rapids Hospitals - Butterworth Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Kathleen Y. Butler
-
Grosse Pointe Woods, Michigan, Estados Unidos, 48236
- Recrutamento
- Henry Ford Saint John Hospital - Breast
-
Contato:
- Site Public Contact
- Número de telefone: 313-343-3166
- E-mail: karen.forman@ascension.org
-
Investigador principal:
- Tareq Al baghdadi
-
Grosse Pointe Woods, Michigan, Estados Unidos, 48236
- Recrutamento
- Henry Ford Saint John Hospital - Academic
-
Investigador principal:
- Tareq Al baghdadi
-
Contato:
- Site Public Contact
- Número de telefone: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Grosse Pointe Woods, Michigan, Estados Unidos, 48236
- Recrutamento
- Henry Ford Saint John Hospital - Van Elslander
-
Investigador principal:
- Tareq Al baghdadi
-
Contato:
- Site Public Contact
- Número de telefone: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Jackson, Michigan, Estados Unidos, 49201
- Recrutamento
- Allegiance Health
-
Contato:
- Site Public Contact
- Número de telefone: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Investigador principal:
- Haythem Y. Ali
-
Kalamazoo, Michigan, Estados Unidos, 49007
- Recrutamento
- Bronson Methodist Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Kathleen Y. Butler
-
Kalamazoo, Michigan, Estados Unidos, 49007
- Recrutamento
- West Michigan Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Kathleen Y. Butler
-
Lansing, Michigan, Estados Unidos, 48910
- Ativo, não recrutando
- Karmanos Cancer Institute at McLaren Greater Lansing
-
Livonia, Michigan, Estados Unidos, 48154
- Recrutamento
- Trinity Health Saint Mary Mercy Livonia Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Macomb, Michigan, Estados Unidos, 48044
- Recrutamento
- Henry Ford Warren Hospital - Breast Macomb
-
Investigador principal:
- Tareq Al baghdadi
-
Contato:
- Site Public Contact
- Número de telefone: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Macomb, Michigan, Estados Unidos, 48044
- Recrutamento
- Henry Ford Saint John Hospital - Macomb Medical
-
Investigador principal:
- Tareq Al baghdadi
-
Contato:
- Site Public Contact
- Número de telefone: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Muskegon, Michigan, Estados Unidos, 49444
- Recrutamento
- Trinity Health Muskegon Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Tareq Al baghdadi
-
Niles, Michigan, Estados Unidos, 49120
- Recrutamento
- Corewell Health Lakeland Hospitals - Niles Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 616-391-1230
-
Investigador principal:
- Kathleen Y. Butler
-
Norton Shores, Michigan, Estados Unidos, 49444
- Suspenso
- Cancer and Hematology Centers of Western Michigan - Norton Shores
-
Novi, Michigan, Estados Unidos, 48377
- Recrutamento
- Henry Ford Medical Center-Columbus
-
Contato:
- Site Public Contact
- Número de telefone: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Investigador principal:
- Haythem Y. Ali
-
Pontiac, Michigan, Estados Unidos, 48341
- Recrutamento
- Trinity Health Saint Joseph Mercy Oakland Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Reed City, Michigan, Estados Unidos, 49677
- Recrutamento
- Corewell Health Reed City Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Kathleen Y. Butler
-
Royal Oak, Michigan, Estados Unidos, 48073
- Recrutamento
- Corewell Health William Beaumont University Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 248-551-7695
-
Investigador principal:
- Andrew A. Muskovitz
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Recrutamento
- Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Kathleen Y. Butler
-
Saint Joseph, Michigan, Estados Unidos, 49085
- Recrutamento
- Corewell Health Lakeland Hospitals - Saint Joseph Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Kathleen Y. Butler
-
Traverse City, Michigan, Estados Unidos, 49684
- Recrutamento
- Munson Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Kathleen Y. Butler
-
Troy, Michigan, Estados Unidos, 48085
- Recrutamento
- Corewell Health Beaumont Troy Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 248-551-7695
-
Investigador principal:
- Andrew A. Muskovitz
-
Warren, Michigan, Estados Unidos, 48093
- Recrutamento
- Henry Ford Madison Heights Hospital - Breast
-
Investigador principal:
- Tareq Al baghdadi
-
Contato:
- Site Public Contact
- Número de telefone: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Warren, Michigan, Estados Unidos, 48093
- Recrutamento
- Henry Ford Health Warren Hospital
-
Investigador principal:
- Tareq Al baghdadi
-
Contato:
- Site Public Contact
- Número de telefone: 313-343-3166
- E-mail: kforman1@hfhs.org
-
Warren, Michigan, Estados Unidos, 48093
- Recrutamento
- Henry Ford Warren Hospital - GLCMS
-
Investigador principal:
- Tareq Al baghdadi
-
Contato:
- Site Public Contact
- Número de telefone: 313-343-3166
- E-mail: kforman1@hfhs.org
-
West Bloomfield, Michigan, Estados Unidos, 48322
- Recrutamento
- Henry Ford West Bloomfield Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 313-916-3721
- E-mail: CTOResearch@hfhs.org
-
Investigador principal:
- Haythem Y. Ali
-
Wyandotte, Michigan, Estados Unidos, 48192
- Recrutamento
- Henry Ford Wyandotte Hospital
-
Investigador principal:
- Haythem Y. Ali
-
Contato:
- Site Public Contact
- E-mail: nhay@hfhs.org
-
Wyoming, Michigan, Estados Unidos, 49519
- Recrutamento
- University of Michigan Health - West
-
Contato:
- Site Public Contact
- Número de telefone: 616-391-1230
- E-mail: crcwm-regulatory@crcwm.org
-
Investigador principal:
- Kathleen Y. Butler
-
Ypsilanti, Michigan, Estados Unidos, 48106
- Recrutamento
- Huron Gastroenterology PC
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
Ypsilanti, Michigan, Estados Unidos, 48197
- Recrutamento
- Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus
-
Contato:
- Site Public Contact
- Número de telefone: 734-712-7251
- E-mail: MCRCwebsitecontactform@stjoeshealth.org
-
Investigador principal:
- Tareq Al baghdadi
-
-
Minnesota
-
Burnsville, Minnesota, Estados Unidos, 55337
- Recrutamento
- Minnesota Oncology - Burnsville
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Duluth, Minnesota, Estados Unidos, 55805
- Ativo, não recrutando
- Saint Luke's Hospital of Duluth
-
Edina, Minnesota, Estados Unidos, 55435
- Recrutamento
- Fairview Southdale Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Edina, Minnesota, Estados Unidos, 55435
- Recrutamento
- Minnesota Oncology - Edina
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Minneapolis, Minnesota, Estados Unidos, 55407
- Recrutamento
- Abbott-Northwestern Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Minneapolis, Minnesota, Estados Unidos, 55415
- Recrutamento
- Hennepin County Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Rochester, Minnesota, Estados Unidos, 55905
- Recrutamento
- Mayo Clinic in Rochester
-
Investigador principal:
- Jacob Orme
-
Contato:
- Site Public Contact
- Número de telefone: 855-776-0015
-
Saint Louis Park, Minnesota, Estados Unidos, 55416
- Recrutamento
- Park Nicollet Clinic - Saint Louis Park
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Saint Paul, Minnesota, Estados Unidos, 55101
- Recrutamento
- Regions Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Saint Paul, Minnesota, Estados Unidos, 55102
- Recrutamento
- United Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
Shakopee, Minnesota, Estados Unidos, 55379
- Recrutamento
- Saint Francis Regional Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 952-993-1517
- E-mail: mmcorc@healthpartners.com
-
Investigador principal:
- David M. King
-
-
Missouri
-
Cape Girardeau, Missouri, Estados Unidos, 63703
- Recrutamento
- Saint Francis Medical Center
-
Investigador principal:
- Bryan A. Faller
-
Contato:
- Site Public Contact
- Número de telefone: 573-334-2230
- E-mail: sfmc@sfmc.net
-
Joplin, Missouri, Estados Unidos, 64804
- Recrutamento
- Mercy Hospital Joplin
-
Investigador principal:
- Jay W. Carlson
-
Contato:
- Site Public Contact
- Número de telefone: 417-556-3074
- E-mail: esmeralda.carrillo@mercy.net
-
Springfield, Missouri, Estados Unidos, 65804
- Recrutamento
- Mercy Hospital Springfield
-
Investigador principal:
- Jay W. Carlson
-
Contato:
- Site Public Contact
- Número de telefone: 417-269-4520
-
Springfield, Missouri, Estados Unidos, 65807
- Recrutamento
- CoxHealth South Hospital
-
Investigador principal:
- Jay W. Carlson
-
Contato:
- Site Public Contact
- Número de telefone: 417-269-4520
-
St Louis, Missouri, Estados Unidos, 63128
- Recrutamento
- Mercy Hospital South
-
Investigador principal:
- Jay W. Carlson
-
Contato:
- Site Public Contact
- Número de telefone: 314-525-6042
- E-mail: Danielle.Werle@mercy.net
-
-
Montana
-
Anaconda, Montana, Estados Unidos, 59711
- Recrutamento
- Community Hospital of Anaconda
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Billings, Montana, Estados Unidos, 59101
- Recrutamento
- Billings Clinic Cancer Center
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 800-996-2663
- E-mail: research@billingsclinic.org
-
Billings, Montana, Estados Unidos, 59102
- Recrutamento
- Saint Vincent Frontier Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-648-6274
-
Investigador principal:
- Patrick W. Cobb
-
Great Falls, Montana, Estados Unidos, 59405
- Recrutamento
- Benefis Sletten Cancer Institute
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Kalispell, Montana, Estados Unidos, 59901
- Recrutamento
- Logan Health Medical Center
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
Missoula, Montana, Estados Unidos, 59804
- Recrutamento
- Community Medical Center
-
Investigador principal:
- John M. Schallenkamp
-
Contato:
- Site Public Contact
- Número de telefone: 406-969-6060
- E-mail: mccinfo@mtcancer.org
-
-
New Hampshire
-
Lebanon, New Hampshire, Estados Unidos, 03756
- Recrutamento
- Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-639-6918
- E-mail: cancer.research.nurse@dartmouth.edu
-
Investigador principal:
- Kathryn C. Hourdequin
-
-
New York
-
Buffalo, New York, Estados Unidos, 14263
- Ativo, não recrutando
- Roswell Park Cancer Institute
-
New York, New York, Estados Unidos, 10029
- Ativo, não recrutando
- Mount Sinai Hospital
-
Stony Brook, New York, Estados Unidos, 11794
- Ativo, não recrutando
- Stony Brook University Medical Center
-
-
North Carolina
-
Cary, North Carolina, Estados Unidos, 27518
- Suspenso
- Duke Cancer Center Cary
-
Charlotte, North Carolina, Estados Unidos, 28203
- Recrutamento
- Carolinas Medical Center/Levine Cancer Institute
-
Investigador principal:
- Earle F. Burgess
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-9376
-
Charlotte, North Carolina, Estados Unidos, 28210
- Recrutamento
- Atrium Health Pineville/LCI-Pineville
-
Investigador principal:
- Earle F. Burgess
-
Contato:
- Site Public Contact
- Número de telefone: 980-442-2000
-
Charlotte, North Carolina, Estados Unidos, 28211
- Recrutamento
- Levine Cancer Institute-SouthPark
-
Investigador principal:
- Earle F. Burgess
-
Contato:
- Site Public Contact
- Número de telefone: 980-442-2000
-
Charlotte, North Carolina, Estados Unidos, 28262
- Recrutamento
- Atrium Health University City/LCI-University
-
Investigador principal:
- Earle F. Burgess
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-9376
-
Charlotte, North Carolina, Estados Unidos, 28277
- Recrutamento
- Levine Cancer Institute-Ballantyne
-
Investigador principal:
- Earle F. Burgess
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-9376
-
Clinton, North Carolina, Estados Unidos, 28328
- Recrutamento
- Southeastern Medical Oncology Center-Clinton
-
Contato:
- Site Public Contact
- Número de telefone: 919-587-9084
- E-mail: jfields@cancersmoc.com
-
Investigador principal:
- Samer S. Kasbari
-
Concord, North Carolina, Estados Unidos, 28025
- Recrutamento
- Atrium Health Cabarrus/LCI-Concord
-
Investigador principal:
- Earle F. Burgess
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-9376
-
Durham, North Carolina, Estados Unidos, 27710
- Recrutamento
- Duke University Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 888-275-3853
-
Investigador principal:
- Tucker Coston
-
Gastonia, North Carolina, Estados Unidos, 28054
- Recrutamento
- Levine Cancer Institute-Gaston
-
Investigador principal:
- Earle F. Burgess
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-9376
-
Goldsboro, North Carolina, Estados Unidos, 27534
- Recrutamento
- Southeastern Medical Oncology Center-Goldsboro
-
Contato:
- Site Public Contact
- Número de telefone: 919-587-9084
- E-mail: jfields@cancersmoc.com
-
Investigador principal:
- Samer S. Kasbari
-
Jacksonville, North Carolina, Estados Unidos, 28546
- Recrutamento
- Southeastern Medical Oncology Center-Jacksonville
-
Investigador principal:
- Samer S. Kasbari
-
Contato:
- Site Public Contact
- Número de telefone: 910-587-9084
- E-mail: jfields@cancersmoc.com
-
Pinehurst, North Carolina, Estados Unidos, 28374
- Recrutamento
- FirstHealth of the Carolinas-Moore Regional Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 910-715-3500
- E-mail: jcwilliams@firsthealth.org
-
Investigador principal:
- Charles S. Kuzma
-
Raleigh, North Carolina, Estados Unidos, 27609
- Recrutamento
- Duke Cancer Center Raleigh
-
Contato:
- Site Public Contact
- E-mail: NCTNStudyTeam@dm.duke.edu
-
Investigador principal:
- Tucker Coston
-
Shelby, North Carolina, Estados Unidos, 28150
- Recrutamento
- Atrium Health Cleveland/LCI-Cleveland
-
Investigador principal:
- Earle F. Burgess
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-9376
-
-
Ohio
-
Columbus, Ohio, Estados Unidos, 43210
- Recrutamento
- Ohio State University Comprehensive Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-293-5066
- E-mail: Jamesline@osumc.edu
-
Investigador principal:
- Bhavana Konda
-
Toledo, Ohio, Estados Unidos, 43623
- Suspenso
- Toledo Clinic Cancer Centers-Toledo
-
-
Oklahoma
-
Lawton, Oklahoma, Estados Unidos, 73505
- Recrutamento
- Cancer Centers of Southwest Oklahoma Research
-
Contato:
- Site Public Contact
- Número de telefone: 877-231-4440
-
Investigador principal:
- Sagila George
-
Oklahoma City, Oklahoma, Estados Unidos, 73104
- Recrutamento
- University of Oklahoma Health Sciences Center
-
Contato:
- Site Public Contact
- Número de telefone: 405-271-8777
- E-mail: ou-clinical-trials@ouhsc.edu
-
Investigador principal:
- Sagila George
-
Oklahoma City, Oklahoma, Estados Unidos, 73120
- Recrutamento
- Mercy Hospital Oklahoma City
-
Investigador principal:
- Jay W. Carlson
-
Contato:
- Site Public Contact
- Número de telefone: 405-752-3402
-
-
Oregon
-
Bend, Oregon, Estados Unidos, 97701
- Recrutamento
- Saint Charles Health System
-
Contato:
- Site Public Contact
- Número de telefone: 541-706-2909
- E-mail: nosall@stcharleshealthcare.org
-
Investigador principal:
- Charles W. Drescher
-
Clackamas, Oregon, Estados Unidos, 97015
- Suspenso
- Providence Cancer Institute Clackamas Clinic
-
Newberg, Oregon, Estados Unidos, 97132
- Recrutamento
- Providence Newberg Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Investigador principal:
- Charles W. Drescher
-
Oregon City, Oregon, Estados Unidos, 97045
- Recrutamento
- Providence Willamette Falls Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Investigador principal:
- Charles W. Drescher
-
Portland, Oregon, Estados Unidos, 97213
- Recrutamento
- Providence Portland Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Investigador principal:
- Charles W. Drescher
-
Portland, Oregon, Estados Unidos, 97225
- Recrutamento
- Providence Saint Vincent Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 503-215-2614
- E-mail: CanRsrchStudies@providence.org
-
Investigador principal:
- Charles W. Drescher
-
-
Pennsylvania
-
Chambersburg, Pennsylvania, Estados Unidos, 17201
- Recrutamento
- WellSpan Medical Oncology and Hematology
-
Contato:
- Site Public Contact
- Número de telefone: 717-217-6020
-
Investigador principal:
- Marianne Spengler
-
Ephrata, Pennsylvania, Estados Unidos, 17522
- Recrutamento
- Ephrata Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 717-721-4840
-
Investigador principal:
- Marianne Spengler
-
Gettysburg, Pennsylvania, Estados Unidos, 17325
- Recrutamento
- Adams Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 877-441-7957
-
Investigador principal:
- Marianne Spengler
-
Hanover, Pennsylvania, Estados Unidos, 17331
- Recrutamento
- WellSpan Medical Oncology and Hematology
-
Contato:
- Site Public Contact
- Número de telefone: 717-632-1559
-
Investigador principal:
- Marianne Spengler
-
Lebanon, Pennsylvania, Estados Unidos, 17042
- Recrutamento
- Sechler Family Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 717-741-8303
- E-mail: doxenberg@wellspan.org
-
Investigador principal:
- Marianne Spengler
-
York, Pennsylvania, Estados Unidos, 17403
- Recrutamento
- WellSpan Health-York Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 877-441-7957
-
Investigador principal:
- Marianne Spengler
-
York, Pennsylvania, Estados Unidos, 17403
- Suspenso
- Cancer Care Associates of York
-
-
Rhode Island
-
Westerly, Rhode Island, Estados Unidos, 02891
- Recrutamento
- Smilow Cancer Hospital Care Center - Westerly
-
Contato:
- Site Public Contact
- Número de telefone: 203-785-5702
- E-mail: canceranswers@yale.edu
-
Investigador principal:
- Matthew Austin
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29425
- Suspenso
- Medical University of South Carolina
-
Rock Hill, South Carolina, Estados Unidos, 29732
- Recrutamento
- Levine Cancer Institute-Rock Hill
-
Investigador principal:
- Earle F. Burgess
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-9376
-
-
South Dakota
-
Rapid City, South Dakota, Estados Unidos, 57701
- Recrutamento
- Rapid City Regional Hospital
-
Investigador principal:
- Abdel-Ghani Azzouqa
-
Contato:
- Site Public Contact
- Número de telefone: 605-755-2370
- E-mail: research@monument.health
-
-
Tennessee
-
Nashville, Tennessee, Estados Unidos, 37232
- Recrutamento
- Vanderbilt University/Ingram Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-811-8480
-
Investigador principal:
- Robert A. Ramirez
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Recrutamento
- UT Southwestern/Simmons Cancer Center-Dallas
-
Contato:
- Site Public Contact
- Número de telefone: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Investigador principal:
- Namrata I. Peswani
-
Dallas, Texas, Estados Unidos, 75235
- Recrutamento
- Parkland Memorial Hospital
-
Contato:
- Site Public Contact
- Número de telefone: 214-590-5582
- E-mail: canceranswerline@UTSouthwestern.edu
-
Investigador principal:
- Namrata I. Peswani
-
Dallas, Texas, Estados Unidos, 75237
- Recrutamento
- UT Southwestern Simmons Cancer Center - RedBird
-
Investigador principal:
- Namrata I. Peswani
-
Contato:
- Site Public Contact
- Número de telefone: 214-648-7097
- E-mail: canceranswerline@utsouthwestern.edu
-
Fort Worth, Texas, Estados Unidos, 76104
- Recrutamento
- UT Southwestern/Simmons Cancer Center-Fort Worth
-
Contato:
- Site Public Contact
- Número de telefone: 214-648-7097
- E-mail: canceranswerline@UTSouthwestern.edu
-
Investigador principal:
- Namrata I. Peswani
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center
-
Investigador principal:
- Tannaz Armaghany
-
Contato:
- Site Public Contact
- Número de telefone: 713-798-1354
- E-mail: burton@bcm.edu
-
Houston, Texas, Estados Unidos, 77030
- Recrutamento
- Ben Taub General Hospital
-
Investigador principal:
- Tannaz Armaghany
-
Contato:
- Site Public Contact
- Número de telefone: 713-873-2000
-
Richardson, Texas, Estados Unidos, 75080
- Recrutamento
- UT Southwestern Clinical Center at Richardson/Plano
-
Contato:
- Site Public Contact
- Número de telefone: 972-669-7044
- E-mail: Suzanne.cole@utsouthwestern.edu
-
Investigador principal:
- Namrata I. Peswani
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- Recrutamento
- Huntsman Cancer Institute/University of Utah
-
Contato:
- Site Public Contact
- Número de telefone: 888-424-2100
- E-mail: cancerinfo@hci.utah.edu
-
Investigador principal:
- Heloisa P. Soares
-
-
Vermont
-
Saint Johnsbury, Vermont, Estados Unidos, 05819
- Recrutamento
- Dartmouth Cancer Center - North
-
Contato:
- Site Public Contact
- Número de telefone: 800-639-6918
- E-mail: cancer.research.nurse@hitchcock.org
-
Investigador principal:
- Kathryn C. Hourdequin
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- Recrutamento
- University of Washington Medical Center - Montlake
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-8824
-
Investigador principal:
- David B. Zhen
-
Seattle, Washington, Estados Unidos, 98109
- Recrutamento
- Fred Hutchinson Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-804-8824
-
Investigador principal:
- David B. Zhen
-
-
West Virginia
-
Bridgeport, West Virginia, Estados Unidos, 26330
- Recrutamento
- United Hospital Center
-
Contato:
- Site Public Contact
- Número de telefone: 304-293-7374
- E-mail: cancertrialsinfo@hsc.wvu.edu
-
Investigador principal:
- Nour Daboul
-
Morgantown, West Virginia, Estados Unidos, 26506
- Recrutamento
- West Virginia University Healthcare
-
Contato:
- Site Public Contact
- Número de telefone: 304-293-7374
- E-mail: cancertrialsinfo@hsc.wvu.edu
-
Investigador principal:
- Nour Daboul
-
-
Wisconsin
-
Eau Claire, Wisconsin, Estados Unidos, 54701
- Recrutamento
- Marshfield Medical Center-EC Cancer Center
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Dean A. Delmastro
-
La Crosse, Wisconsin, Estados Unidos, 54601
- Recrutamento
- Gundersen Lutheran Medical Center
-
Contato:
- Site Public Contact
- Número de telefone: 608-775-2385
- E-mail: cancerctr@gundersenhealth.org
-
Investigador principal:
- David E. Marinier
-
Marshfield, Wisconsin, Estados Unidos, 54449
- Recrutamento
- Marshfield Medical Center-Marshfield
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Dean A. Delmastro
-
Milwaukee, Wisconsin, Estados Unidos, 53226
- Recrutamento
- Medical College of Wisconsin
-
Contato:
- Site Public Contact
- Número de telefone: 414-805-3666
-
Investigador principal:
- Alexandria T. Phan
-
Minocqua, Wisconsin, Estados Unidos, 54548
- Recrutamento
- Marshfield Medical Center - Minocqua
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Dean A. Delmastro
-
Rice Lake, Wisconsin, Estados Unidos, 54868
- Recrutamento
- Marshfield Medical Center-Rice Lake
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Dean A. Delmastro
-
Stevens Point, Wisconsin, Estados Unidos, 54482
- Recrutamento
- Marshfield Medical Center-River Region at Stevens Point
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Dean A. Delmastro
-
Weston, Wisconsin, Estados Unidos, 54476
- Recrutamento
- Marshfield Medical Center - Weston
-
Contato:
- Site Public Contact
- Número de telefone: 800-782-8581
- E-mail: oncology.clinical.trials@marshfieldresearch.org
-
Investigador principal:
- Dean A. Delmastro
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
-
Participants must have histologically-confirmed (local site pathological confirmation sufficient) extrapulmonary poorly differentiated, neuroendocrine carcinoma (NEC)
-
Participants must have disease that is unresectable or metastatic and not eligible for definitive therapy as deemed per the treating investigator
-
Participants must have radiologically evaluable disease, measurable or non-measurable, per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 criteria. All measurable and nonmeasurable lesions must be assessed by CT scan with IV contrast of the chest/abdomen/and pelvis (or CT chest without contrast and MRI abdomen/pelvis with gadolinium contrast, if contraindication to CT iodinated contrast) within 28 days prior to registration. While may be used for routine clinical evaluation, PET scans and bone scans alone are not acceptable for disease assessment while participating in this study. All known sites of disease must be assessed and documented on the Baseline Tumor Assessment Form
-
Participants must have brain MRI (or CT head with contrast if there is contraindication to MRI brain) if clinically indicated within 28 days prior to registration. Note: Brain imaging is not required in participants without known and/or clinical concern for brain metastases. Participants with asymptomatic central nervous system (CNS) metastases are eligible if one or more of the following apply:
-
Participants who have received treatment for brain metastases must have:
- No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration
- Discontinued all corticosteroids at least 14 days prior to registration
-
Participants with treatment-naive brain lesions must have:
- No lesion measuring > 2.0 cm in size in any axis
- MRI brain or CT head with contrast (if there is contraindication to MRI brain) demonstrating no evidence for mass effect, edema, or other impending neurological compromise within 28 days prior to registration
- No evidence of radiological progression (by MRI brain or CT head with contrast if there is contraindication to MRI brain) within 28 days prior to registration
- No need for > 2 mg of dexamethasone (or equivalent of > 10 mg prednisone) per day at time of registration
-
-
Participants must not have symptomatic central nervous system (CNS) metastases
-
Participants must not have known or suspected leptomeningeal disease
-
Participants with prior history of non-metastatic (localized/locally advanced disease) extrapulmonary poorly differentiated NEC may have had prior platinum-based therapy +/- radiation +/- surgery provided that all therapy was completed >= 6 months prior to registration
-
Participants must discontinue denosumab prior to study registration and plan to replace with a bisphosphonate while on the study
-
Participants must not have had prior treatment for advanced or metastatic NEC EXCEPT one cycle of platinum (carboplatin/cisplatin) + etoposide is allowed prior to registration. Other chemotherapy regimens are not allowed. For participants with prostate or urothelial NEC, prior chemotherapy for the non-NEC component (e.g. adenocarcinoma or urothelial) is allowed as long as such therapy was completed >= 24 weeks prior to registration and participants have recovered from all prior toxicities to =< grade 1.
-
Participants must not have had prior treatment with an anti-PD-1, anti-PD-L1, antiPD-L2, CD137 agonists, anti-CTLA-4 agent, or any other immune checkpoint inhibitors for any neuroendocrine neoplasm. Immune checkpoint inhibitors given for other cancer indications are allowed provided last therapy was given at least 12 months prior to study registration
-
Participants must not have received treatment with systemic immunostimulatory agents including, but not limited to, interferon and interleukin2 [IL-2] within 4 weeks or 5 half-lives of the drug (whichever is longer) prior to registration
-
Participants must not have had history of known severe allergy, anaphylactic, or other hypersensitivity reactions to chimeric or humanized antibodies, including to Chinese hamster ovary cell products or to any component of the atezolizumab formulation, cisplatin, carboplatin, or etoposide
-
Participants must not be on active systemic therapy for another cancer with the exception of hormonal therapy including androgen deprivation therapy (e.g., gonadotropin-releasing hormone [GnRH] agonists or antagonists), which can be continued while participants are receiving protocol therapy. Use of enzalutamide or apalutamide is permitted after completion of chemotherapy and must be held during chemotherapy for participants receiving prior to enrollment. Use of darolutamide is permitted during chemotherapy. Glucocorticoid-containing regimens, including abiraterone, are not permitted.
-
Participants must be >= 18 years of age
-
Participants must have a Zubrod performance status of =< 2 within 28 days prior to registration
-
Participants must have a complete medical history and physical exam within 28 days prior to registration
-
Absolute neutrophil count (ANC) >= 1.5 x 10^9 /L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
-
Hemoglobin >= 9.0 g/dl (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
-
Platelet count >= 100 x 10^9/L (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
-
Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 2.5 x institutional upper limit of normal (ULN) (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
-
Serum total bilirubin =< 1.5 x ULN (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
-
Adequate renal function as defined by any 1 of the following: 1) Measured creatinine clearance (CL) > 50 mL/min OR 2) Calculated creatinine CL > 50 mL/min by the Cockcroft-Gault formula OR by 24-hour urine collection for determination of creatinine clearance (obtained within 14 days prior to registration. For participants who received a cycle of chemotherapy prior to registration, at least 21 days must have elapsed between day 1 of platinum + etoposide and performance of these tests)
-
Participants must not have uncontrolled or symptomatic hypercalcemia (> 1.5 mmol/L ionized calcium or calcium > 12 mg/dL or corrected serum calcium > ULN) within 14 days prior to registration. Participants who have asymptomatic hypercalcemia are eligible provided that medical therapy to treat the hypercalcemia is planned
-
Participants must not have a diagnosis of immunodeficiency nor be receiving systemic steroid therapy (equivalent of > 20 mg of hydrocortisone per day) or any other form of immunosuppressive therapy within 14 days prior to registration
-
Participants must not have active or history of autoimmune disease or immune deficiency, including, but not limited to myasthenia gravis, myositis, autoimmune hepatitis, systemic lupus erythematosus, rheumatoid arthritis, inflammatory bowel disease, antiphospholipid antibody syndrome, Wegener granulomatosis, Sjogren syndrome, Guillain-Barre syndrome, or multiple sclerosis with the following exceptions:
-
Patients with a history of autoimmune-related hypothyroidism who are on thyroid-replacement hormone are eligible for the study
-
Patients with controlled type 1 diabetes mellitus who are on an insulin regimen are eligible for the study
-
Patients with eczema, psoriasis, lichen simplex chronicus, or vitiligo with dermatologic manifestations only (e.g., patients with psoriatic arthritis are excluded) are eligible for the study provided all of following conditions are met:
- Rash must cover < 10% of body surface area
- Disease is well controlled at baseline and requires only low-potency topical corticosteroids
- No occurrence of acute exacerbations of the underlying condition requiring psoralen plus ultraviolet A radiation, methotrexate, retinoids, biologic agents, oral calcineurin inhibitors, or high-potency or oral corticosteroids within the previous 12 months
-
-
Participants must not have history of idiopathic pulmonary fibrosis, organizing pneumonia (e.g., bronchiolitis obliterans), drug-induced pneumonitis, idiopathic pneumonitis, or evidence of active pneumonitis on screening chest CT scan. NOTE: History of radiation pneumonitis in the radiation field (fibrosis) is permitted
-
Participants must not have significant cardiovascular disease, such as New York Heart Association class II or greater cardiac disease, myocardial infarction within 3 months prior to registration, unstable arrythmias, or unstable angina
-
Participants must not have had a major surgical procedure other than for diagnosis within 28 days prior to registration. Participant must not plan to receive a major surgical procedure during the course of protocol treatment. NOTE: Patient port placement is not considered a major surgery
-
Participants must not have severe infections (i.e., Common Terminology Criteria for Adverse Events [CTCAE] grade >= 2) at time of registration, including but not limited to hospitalization for complications for infection, bacteremia, or severe pneumonia
-
Participants must not have known active tuberculosis
-
Participants with evidence of chronic hepatitis B virus (HBV) infection must have undetectable HBV viral load, with testing performed as clinically indicated
-
Participants with a history of hepatitis C virus (HCV) infection must have been treated and cured. Participants with active HCV infection who are currently on treatment must have an undetectable HCV viral load, with testing performed as clinically indicated
-
Participants with known human immunodeficiency virus (HIV)-infection must be on effective anti-retroviral therapy at time of registration and have undetectable HIV viral load within 6 months of registration
-
Participants must not have prior allogeneic bone marrow transplantation or solid organ transplant
-
Participants must not have received administration of a live, attenuated vaccine (e.g., FluMist [registered trademark]) within 28 days prior to initiation of study treatment, during treatment with atezolizumab, and not plan to receive for 5 months after the last dose of atezolizumab
-
Participants must not be pregnant due to the possibility of harm to the fetus. Individuals who are of reproductive potential must have agreed to use an effective contraceptive method (with details provided as a part of the consent process) during the treatment period and for 5 months after the final dose of atezolizumab. A person who has had menses at any time in the preceding 12 consecutive months or who has semen likely to contain sperm is considered to be of "reproductive potential." In addition to routine contraceptive methods, "effective contraception" also includes refraining from sexual activity that might result in pregnancy and surgery intended to prevent pregnancy (or with a side effect of pregnancy prevention) including hysterectomy, bilateral oophorectomy, bilateral tubal ligation/occlusion, and vasectomy with testing showing no sperm in the semen
-
Participants must be offered the opportunity to participate in specimen banking. With participant consent, specimens must be collected and submitted via the Southwest Oncology Group (SWOG) Specimen Tracking System
-
Participants must be informed of the investigational nature of this study and must sign and give informed consent in accordance with institutional and federal guidelines
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: Arm I (atezolizumab, platinum drug, etoposide)
During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. During maintenance phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle. Treatment repeats every 21 days for up to 17 cycles in the absence of disease progression or unacceptable toxicity. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study. |
Given IV
Outros nomes:
Given IV
Outros nomes:
Undergo blood sample collection
Outros nomes:
Undergo MRI
Outros nomes:
Given IV
Outros nomes:
Undergo CT scan
Outros nomes:
Given IV
Outros nomes:
|
|
Experimental: Arm II (atezolizumab, platinum drug, etoposide, observation)
During induction phase, patients receive atezolizumab IV over 30-60 minutes on day 1 of each cycle, carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle, and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study. (CLOSED TO ACCRUAL 7/9/26) |
Given IV
Outros nomes:
Given IV
Outros nomes:
Undergo blood sample collection
Outros nomes:
Undergo MRI
Outros nomes:
Given IV
Outros nomes:
Undergo CT scan
Outros nomes:
Undergo observation
Outros nomes:
Given IV
Outros nomes:
|
|
Comparador Ativo: Arm III (platinum drug, etoposide, observation)
During induction phase, patients receive carboplatin IV over 30 minutes or cisplatin IV over 60 minutes on day 1 of each cycle and etoposide IV on days 1-3 of each cycle. Treatment repeats every 21 days for 4 cycles in the absence of disease progression or unacceptable toxicity. Patients then undergo observation for 1 year. Patients also undergo CT scan and/or MRI throughout the trial and blood sample collection on study. |
Given IV
Outros nomes:
Given IV
Outros nomes:
Undergo blood sample collection
Outros nomes:
Undergo MRI
Outros nomes:
Given IV
Outros nomes:
Undergo CT scan
Outros nomes:
Undergo observation
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Overall survival
Prazo: From date of registration or from date of start of observation/maintenance therapy to date of death due to any cause, assessed up to 5 years
|
Log-rank tests stratified by the randomization stratification factors will be used for null hypothesis (efficacy) tests. Cox regression models stratified by the randomization stratification factors will be used for alternative hypothesis (futility) tests. |
From date of registration or from date of start of observation/maintenance therapy to date of death due to any cause, assessed up to 5 years
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Progression-free survival
Prazo: From date of registration or start of observation/maintenance therapy to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 5 years
|
Will be estimated using the Kaplan-Meier method and compared using log-rank tests. |
From date of registration or start of observation/maintenance therapy to date of first documentation of progression or symptomatic deterioration, or death due to any cause, assessed up to 5 years
|
|
Duration of response
Prazo: Time from date of initial response to date of progression or death, assessed up to 5 years
|
Will be estimated non-parametrically using cumulative incidence curves. |
Time from date of initial response to date of progression or death, assessed up to 5 years
|
|
Objective response rate (confirmed complete response [CR] or partial response [PR])
Prazo: Up to 5 years from study enrollment
|
Will be tabulated and compared between arms using Fisher's exact test. |
Up to 5 years from study enrollment
|
|
Clinical benefit rate (confirmed CR or PR of any amount of time or stable disease for 6 months or longer)
Prazo: Up to 5 years from study enrollment
|
Will be tabulated and compared between arms using Fisher's exact test. |
Up to 5 years from study enrollment
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Investigador principal: David B Zhen, SWOG Cancer Research Network
Publicações e links úteis
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
- Administração de Serviços de Saúde
- Produtos químicos orgânicos
- Técnicas de investigação
- Métodos
- Técnicas de laboratório clínico
- Técnicas e procedimentos de diagnóstico
- Diagnóstico
- Hidrocarbonetos
- Hidrocarbonetos, cíclicos
- Qualidade de assistência médica
- Carboidratos
- Podofillotoxina
- Tetra -hidonaftaleno
- Naftalenos
- Hidrocarbonetos aromáticos policíclicos
- Hidrocarbonetos, aromáticos
- Compostos policíclicos
- Glucosídeos
- Glicosídeos
- Produtos químicos inorgânicos
- Compostos de cloro
- Compostos de nitrogênio
- Complexos de coordenação
- Elementos
- Metais
- Técnicas de química, analíticas
- Análise de espectro
- Metais, pesados
- Compostos de platina
- Avaliação de resultados, assistência médica
- Avaliação de resultados e processos, assistência médica
- Elementos de transição
- Etoposídeo
- Carboplatina
- Cisplatina
- Citrato de 1,2-diaminociclohexanoplatina II
- Observação
- Manipulação de amostras
- Espectroscopia de ressonância magnética
- Esperando vigilante
- Platina
- Atezolizumab
Outros números de identificação do estudo
- NCI-2021-09851
- U10CA180888 (Concessão/Contrato do NIH dos EUA)
- NCI-2021-09851 (Identificador de registro: CTRP (Clinical Trial Reporting Program))
- S2012 (Outro identificador: CTEP)
- S2012 (Outro identificador: SWOG)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .